Antitumor and antiangiogenic activity of cediranib in a preclinical model of renal cell carcinoma.
Cediranib is a highly potent and selective vascular endothelial growth factor (VEGF) signaling inhibitor with activity against all three VEGF receptors (VEGFRs) that inhibits angiogenesis and growth of human tumor xenografts in vivo. The present study evaluated the antitumor and antiangiogenic activ...
Main Authors: | Medinger, M, Esser, N, Zirrgiebel, U, Ryan, A, Jürgensmeier, J, Drevs, J |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2009
|
Similar Items
-
Antitumor effect of the vascular-disrupting agent ZD6126 in a murine renal cell carcinoma model.
by: Medinger, M, et al.
Published: (2011) -
Preclinical evaluation of discorhabdin in antiangiogenic and antitumor models
by: Harris, E, et al.
Published: (2018) -
Preclinical Evaluation of Discorhabdins in Antiangiogenic and Antitumor Models
by: Emily M. Harris, et al.
Published: (2018-07-01) -
Evaluation of novel combined carbogen USPIO (CUSPIO) imaging biomarkers in assessing the antiangiogenic effects of cediranib (AZD2171) in rat C6 gliomas.
by: Burrell, J, et al.
Published: (2012) -
Evaluation of novel combined carbogen USPIO (CUSPIO) imaging biomarkers in assessing the antiangiogenic effects of cediranib (AZD2171) in rat C6 gliomas
by: Burrell, J, et al.
Published: (2012)